<DOC>
	<DOC>NCT01606111</DOC>
	<brief_summary>The purpose of this trial is to investigate safety and efficacy of Cerebrolysin as add-on therapy to standard care in patients with acute traumatic brain injury (TBI). The study duration for each patient is 180 days.</brief_summary>
	<brief_title>The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Cerebrolysin</mesh_term>
	<criteria>Clinical diagnosis of TBI and a GCS 712 Only isolated TBI CT PreTrauma KarnofskyIndex = 100 Age 1860 years Male and female patients Time to needle for study medication within 6 hours after injury Patient is not pregnant or lactating during the trial and is not of childbearing potential Patient was able to speak, read and write in a predefined study language before the accident. Reasonable expectation of completion of outcome measures at followup Written informed consent Evidence of preexisting major health problems Any neurological or nonneurological condition independent from TBI that might influence the functional outcome or other efficacy outcome measures Injury of writing hand influencing cognitive or other outcome measures Clear clinical signs of intoxication influencing the evaluation Major drug dependency including alcohol Chronic treatment with steroids, Ca2+channel blockers or major anticoagulants Penetrating highvelocity missile head trauma Stab wound trauma into the brain Patients with spinal cord injury</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>